US Pharma MarketingAstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval
AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the rare disease drug candidate to a 62% improvement in survival in a prespecified subgroup.
Source: FierceBiotech